MedTrace Logo

Safety and Efficacy Study of Dronabinol to Treat Obstructive Sleep Apnea

NCT01755091 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2021-07-29

Study results available
· View outcomes & findings →

Summary

This is a proof of concept study to determine the safety and efficacy of dronabinol for the treatment of obstructive sleep apnea syndrome (OSA).

Conditions

  • Sleep Apnea, Obstructive

Interventions

DRUG

Dronabinol

DRUG

Placebo (for Dronabinol)

Sponsors & Collaborators

  • Northwestern University

    collaborator OTHER

  • University of Chicago

    collaborator OTHER

  • Hektoen Institute for Medical Research

    collaborator OTHER

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • University of Illinois at Chicago

    lead OTHER

Principal Investigators

  • David W Carley, PhD · University of Illinois at Chicago

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2016-06-30
Completion
2016-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01755091 on ClinicalTrials.gov